Funding Tracker/Vitroscope
Seed plus non-dilutive funding · Pharma & Drug Discovery · Norway
Vitroscope: Seed plus non-dilutive funding
Announced November 3, 2026
The round
The SignalVitroscope announced $7 million combined: $5 million seed co-led by Cerberus Ventures and YZR Capital plus $2 million non-dilutive funding from the Research Council of Norway. The company reports $8.8 million raised to date. Funding supports commercial rollout of vitro.alive and development of vitro.scale for 96 parallel experiments, with customer testing expected in 2027 and launch planned in 2028.
What Vitroscope does
Live human tissue perfusion platforms for drug discovery and experimental research.
Vitroscope develops perfusion platforms with real-time control of oxygen, pH and temperature plus live-cell imaging. Its vitro.alive benchtop platform runs six independent parallel experiments on standard inverted microscopes. On November 3, 2026 it announced $7 million in combined funding: $5 million seed and $2 million non-dilutive funding. The company reports $8.8 million raised to date. Its vitro.scale platform is in development for 96 parallel experiments, with customer testing expected in 2027 and launch planned in 2028. Carlo Kriesi is co-founder and CEO.
Full Vitroscope profile- Company
- Vitroscope
- Consideration
- $7M
- Stage
- Seed plus non-dilutive funding
- Announced
- November 3, 2026
- Led by
- Cerberus Ventures, YZR Capital
- Other investors
- Arcas Ventures, Golden Egg Check, Devico Invest, Angel investors
- Vertical
- Pharma & Drug Discovery
- Country
- Norway